The ichthyoses are a family of genetic skin diseases characterized by dry, thickened, scaling skin. Dermatologists estimate that there are over twenty varieties of ichthyosis, with a wide range of severity and associated symptoms. This registry is designed to identify people in the United States with the ichthyoses and other related disorders and to collect information about their skin ailment and how it has affected them.
A team of scientists from the University of Colorado School of Medicine and the Charles C. Gates Center for Regenerative Medicine at CU Anschutz has reported a more efficient approach to reprogramming a patient's diseased skin cells into stem cells, raising hopes for future clinical trials and potential cures for critical illnesses.
Nagoya University research identified a patient with the whole-body skin disease epidermolytic ichthyosis that had been inherited as a germline mutation from her father with the milder epidermolytic nevus.
Scientists have uncovered evidence that a deficiency in the skin's barrier is key to triggering eczema. The team at Newcastle University, in collaboration with scientists at Stiefel, a GSK company, have identified how a key skin barrier protein called filaggrin impacts on other proteins and pathways in the skin, which in turn drive the development of eczema.
Scientists have identified the gene responsible for generating acylceramide, the key lipid in forming the skin barrier that protects us from pathogens, allergens and other harmful substances. This finding could prove crucial in developing medicines for treating atopic dermatitis and ichthyosis.
A team of New York-based researchers has compared the effects of two disease-causing mutations, potentially explaining why patients with the rare genetic disorder keratitis-ichthyosis-deafness (KID) syndrome can experience different sets of symptoms.
Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.
The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.
Canadian researchers announce the discovery of MEDNIK Syndrome, a debilitating genetic syndrome.
Many people have noticed that as soon as you start using a skin cream, you have to continue with it; if you stop lubricating, your skin becomes drier than when you started. And now there is research to confirm for the first time that normal skin can become drier from creams. Izabela Buraczewska presents these findings in the dissertation she is publicly defending at Uppsala University in Sweden on October 24.
New knowledge points to the fact that a genetically induced lack of filaggrin, a key protein of the skin barrier, plays a decisive role in the origin of allergies.
Experts, lead by the University of Dundee, have discovered the gene which causes genetic skin conditions affecting millions of people.